The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach
Open accessAbstract
Clinical breakpoints are used in clinical microbiology laboratories to categorize microorganisms as clinically susceptible (S), intermediate (I) or resistant (R) dependent on the quantitative antimicrobial susceptibility as indicated by the MIC value determined in a well-defined standard test system. The laboratory report, with the designations of S, I or R for each antimicrobial agent, provides guidance to clinicians with respect to the potential use of agents in the treatment of patients, and clinical breakpoints should therefore distinguish between patients that are likely or unlikely to respond to antimicrobial treatment. In Europe, clinical breakpoints are set by the European Committee on Antimicrobial Susceptibility Testing (EUCAST), following a defined procedure. This includes evaluation of efficacy in experimental settings and clinical studies to derive pharmacodynamic targets such as the fAUC/MIC ratio or %fT > MIC required for efficacy, the pharmacokinetic properties of the agent, Monte Carlo simulations to estimate exposures of the antimicrobial agent in the target patient population and commonly used dosing regimens. The probability of target attainment is subsequently determined for a range of pharmacodynamic targets and the results from the Monte Carlo simulations. The breakpoints derived are subsequently evaluated with respect to the wild-type population of the target microorganisms, specific resistance mechanisms and other relevant data. In this paper, we provide an overview of the EUCAST process and considerations for setting pharmacokinetic/pharmacodynamic breakpoints. These are the breakpoints that in the EUCAST breakpoint tables are referred to as 'non-species-related breakpoints'.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Ambrose, P. G., Bhavnani, S. M., Rubino, C. M., Louie, A., Gumbo, T., Forrest, A., & Drusano, G. L. (2007) · Clinical Infectious Diseases · doi:10.1086/510079 · Cited by 697
EUCAST expert rules in antimicrobial susceptibility testing
Leclercq, R., Cantón, R., Brown, D. F. J., Giske, C. G., Heisig, P., MacGowan, A. P., Mouton, J. W., Nordmann, P., Rodloff, A. C., Rossolini, G. M., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03703.x · Cited by 683
Self-citationCraig, W. A. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00065-5 · Cited by 556
Mouton, J. W., Dudley, M. N., Cars, O., Derendorf, H., & Drusano, G. L. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki079 · Cited by 549
Self-citationEuropean harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria
Kahlmeter, G. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg312 · Cited by 397
Self-citationOptimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria
Kashuba, A. D. M., Nafziger, A. N., Drusano, G. L., & Bertino, J. S. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.3.623 · Cited by 380
Roberts, J. A., Kirkpatrick, C. M. J., Roberts, M. S., Robertson, T. A., Dalley, A. J., & Lipman, J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp139 · Cited by 347
Ambrose, P. G., Grasela, D. M., Grasela, T. H., Passarell, J., Mayer, H. B., & Pierce, P. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2793-2797.2001 · Cited by 299
A Brief Introduction to Monte Carlo Simulation
Bonate, P. L. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140010-00002 · Cited by 243
Cited by
Microbiological effects of sublethal levels of antibiotics
Andersson, D. I., & Hughes, D. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3270 · Cited by 1,757
Ecological effects of antibiotics on natural ecosystems: A review
Grenni, P., Ancona, V., & Barra Caracciolo, A. (2018) · Microchemical Journal · doi:10.1016/j.microc.2017.02.006 · Cited by 1,257
The negative impact of antibiotic resistance
Friedman, N. D., Temkin, E., & Carmeli, Y. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.12.002 · Cited by 870
Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria
van Ingen, J., Boeree, M. J., van Soolingen, D., & Mouton, J. W. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.04.001 · Cited by 351
Self-citationPharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs
Nielsen, E. I., & Friberg, L. E. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005769 · Cited by 332
Metadata
- Authors
- Mouton, J. W., Brown, D. F. J., Apfalter, P., Cantón, R., Giske, C. G., Ivanova, M., MacGowan, A. P., Rodloff, A., Soussy, C.-J., Steinbakk, M., & Kahlmeter, G.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 18
- Issue
- 3
- Pages
- E37-E45
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W2145484866
- Cited by
- 286
- References
- 29
- FWCI
- 6.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. https://app.cochat.ai/papers/10.1111/j.1469-0691.2011.03752.x
- The paper
- Mouton, J. W., Brown, D. F. J., Apfalter, P., Cantón, R., Giske, C. G., Ivanova, M., MacGowan, A. P., Rodloff, A., Soussy, C.-J., Steinbakk, M., & Kahlmeter, G. (2012). The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clinical Microbiology and Infection. https://doi.org/10.1111/j.1469-0691.2011.03752.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
